<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130935</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-GAL-NEX-2010/1</org_study_id>
    <nct_id>NCT01130935</nct_id>
  </id_info>
  <brief_title>Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking Nexium</brief_title>
  <official_title>A National, Multicentre, Open-label, Non-comparative, Non-interventional Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking Nexium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effectiveness of Nexium at alleviating upper GI symptoms in
      subjects and evaluate with which treatment regimen and on which indications acid suppression
      with isomeric proton pump inhibitor is used in routine clinical practice in Albania.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of upper GI symptoms and the overall patient's discomfort during the last week.</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of upper GI symptoms and the overall patient's discomfort during the last week.</measure>
    <time_frame>Week 2-4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of upper GI symptoms and the overall patient's discomfort during the last week.</measure>
    <time_frame>Weeks 8-12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To follow the frequency, type and severity of symptoms in subjects consulting the doctors with upper GI symptoms.</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate with which treatment regimen and on which indications acid suppression with isomeric proton pump inhibitor is used in routine clinical practice in Albania.</measure>
    <time_frame>Once: Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the tolerability of Nexium in patients with upper GI symptoms by the number of participants with adverse events.</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To follow the frequency, type and severity of symptoms in subjects consulting the doctors with upper GI symptoms.</measure>
    <time_frame>Weeks 2-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To follow the frequency, type and severity of symptoms in subjects consulting the doctors with upper GI symptoms.</measure>
    <time_frame>Weeks 8-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the tolerability of Nexium in patients with upper GI symptoms by the number of participants with adverse events.</measure>
    <time_frame>Weeks 2-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the tolerability of Nexium in patients with upper GI symptoms by the number of participants with adverse events.</measure>
    <time_frame>Weeks 8-12</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">491</enrollment>
  <condition>Gastric Acid Suppression</condition>
  <condition>Proton Pump Inhibitors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female subjects, age &gt; 18 years, having had upper GI symptoms requiring acid
        suppression treatment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have had upper GI symptoms requiring acid suppression treatment

          -  Treatment with Nexium is in accordance with indications and dosing approved in
             Albania.

          -  Start of treatment at least 2 weeks prior to enrollment to this study 5. Written
             informed consent is signed.

        Exclusion Criteria:

          -  Known hypersensitivity to Nexium or any other constituents of the formulation

          -  Concomitant administration of atazanavir and nelfinavir.

          -  Alarming upper GI symptoms (i.e. significant unintended weight loss, vomiting,
             dysphasia, hematemesis, melena, fever, jaundice or any other sign indicating serious
             or malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karin Otter, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Director BBC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Senka Riza</last_name>
    <role>Study Chair</role>
    <affiliation>Medical and Regulatory Manager</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Skerdi Prifti, Asc.Proff.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Center &quot;Mother Teresa&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berat</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burrel</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durres</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elbasan</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fier</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kavaje</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Korce</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kruje</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lezhe</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lushnje</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peshkopi</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shkoder</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tirane</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vlore</city>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Albania</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>February 23, 2011</last_update_submitted>
  <last_update_submitted_qc>February 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>MC MD</name_title>
    <organization>AstraZeneca Albania</organization>
  </responsible_party>
  <keyword>GERD</keyword>
  <keyword>gastric and duodenal ulcers</keyword>
  <keyword>NSAID therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

